Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.58 |
| ▸ | ACP1 | P24666 | 5/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | DUSP26 | Q9BV47 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19119994 | 0.89 | FAAH (0.54) | FAAHMEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL22420192 | 0.86 | MEN1 (0.51) | FAAHMEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL19121025 | 0.85 | MEN1 (0.50) | FAAHMEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL17302128 | 0.85 | FAAH (0.89) | FAAHMEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL11319299 | 0.83 | FAAH (0.84) | FAAHMEN1ALDH1A1KMT2AS1PR1 | |
| SCHEMBL17302141 | 0.83 | FAAH (0.84) | FAAHMEN1ALDH1A1KMT2AS1PR1 | |
| SCHEMBL17295325 | 0.83 | FAAH (0.84) | FAAHMEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL17295326 | 0.83 | FAAH (0.84) | FAAHMEN1ALDH1A1KMT2APTPN1 | |
| SCHEMBL17302127 | 0.83 | S1PR1 (0.77) | FAAHMEN1ALDH1A1KMT2AS1PR1 | |
| SCHEMBL21297620 | 0.82 | MEN1 (0.53) | FAAHMEN1ALDH1A1KMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774077-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | UNIVERSITAT BERN (CH) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774077-B2 | Substituted 2-imino-1,3-thiazolidin-4-ones as N-arachidonoylethanolamine cellular uptake inhibitors | CNR2, CNR1, GPR18 | FAAH 4/4885MEN1 4053/4885ALDH1A1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.